Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1824 • 2019 ACR/ARP Annual Meeting
Perceived Stress Independently Associates with Worse Type 2 Symptoms in Systemic Lupus Erythematosus
Sarah Patterson¹, Laura Trupin ¹, Cristina Lanata ¹, Louise Murphy ², Wendy Hartogenesis ¹, Maria Dall'Era ¹, Jinoos Yazdany ³ and Patricia Katz ¹, ¹University of California, San Francisco, San Francisco, CA, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: A new posited framework for categorizing patients with systemic lupus erythematosus (SLE) is the division of symptomatology into two groups: type 1 manifestations represent…
Abstract Number: 2032 • 2019 ACR/ARP Annual Meeting
Enhanced IFN a Production and STING Pathway in Monocytes in Systemic Lupus Erythematosus Is Suppressed by the Inhibition of mTOR Activation
Goh Murayama¹, Asako Chiba ², Ayako Makiyama ³, Taiga Kuga ⁴, Ken Yamaji ⁴, Naoto Tamura ⁴ and Sachiko Miyake ², ¹Department of Internal Medicine and Rhumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, ³Juntendo University School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Interferona (IFNa) is increased and plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). Overexpression of type I IFN regulated genes…
Abstract Number: 2517 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Is a Modifiable Predictor of Durable LLDAS
Hakan Babaoglu¹, Jessica Li ², Daniel Goldman ³, Laurence Magder ⁴ and Michelle Petri ², ¹Gazi University School of Medicine, Ankara, Turkey, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: The Lupus Low Disease Activity State (LLDAS), a potential treat to target goal in systemic lupus erythematosus (SLE), has been found to correlate with…
Abstract Number: 2552 • 2019 ACR/ARP Annual Meeting
Design and Development of an Online Intervention for Lupus Self-Management Based on the Transtheoretical Model of Change
Sarah Gilman ¹, Deborah Levesque ², Carol Cummins ³, Daniel Wallace ⁴, Victoria Werth ⁵ and Patricia Davidson⁶, ¹Wayfinder Health Strategies, Washington, DC, ²Pro-Change Behavior Systems, Providence, RI, ³Pro-Change Behavior Systems, Inc.,, Providence, ⁴Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁵Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶Lupus Foundation of America, Washington, DC
Background/Purpose: The Lupus Foundation of America is in Year 4 of a 6-year cooperative agreement with the Centers for Disease Control and Prevention to develop…
Abstract Number: 2780 • 2019 ACR/ARP Annual Meeting
Identification of SLE Subgroups at Risk for Poor Outcomes After Hydroxychloroquine Taper or Discontinuation
Celline C. Almeida-Brasil ¹, Evelyne Vinet ², Christian Pineau ² and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The risks and benefits of long-term hydroxychloroquine (HCQ) use in systemic lupus erythematosus (SLE), versus tapering or stopping, remain uncertain. We aimed to identify predictors of…
Abstract Number: 67 • 2019 ACR/ARP Annual Meeting
Dermal Lymphatic Dysfunction Is Associated with Disease Activity in the MRL/lpr Lupus Model
Noa Schwartz¹, Thomas Li ², Susan Chyou ², William Shipman ³ and Theresa Lu ⁴, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Weill Cornell Tri-Institutional MD-PhD Program, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine (Microbiology and Immunology), New York
Background/Purpose: Lymphatic vessels are important in limiting the extent and duration of peripheral immune response, both by transporting cellular debris, inflammatory cells and excess interstitial…
Abstract Number: 637 • 2019 ACR/ARP Annual Meeting
How Often Should SLE Patients Be Tested for Lupus Anticoagulant?
Laurence Magder¹ and Michelle Petri ², ¹University of Maryland School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: SLE patients with persistent lupus anticoagulant (LAC) have been observed to be at significantly higher risk of thrombosis. A common clinical definition of persistent…
Abstract Number: 686 • 2019 ACR/ARP Annual Meeting
Association Between the Soluble Terminal Complement Complex C5b-9 (sC5b-9) and Signs of Active Kidney Disease in a Swiss SLE Cohort
Kristin Schmiedeberg ¹, Ruediger B. Mueller ², Thomas Neumann ¹, Ian Pirker ¹, Philipp Rein ³, Camillo Ribi ⁴, Andrea Rubbert-Roth ⁵, Michael Kirschfink ⁶, Reinhard Voll ⁷ and Johannes von Kempis¹, ¹Division of Rheumatology and Immunolog, Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland, ²Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, ³Division of Rheumatology and Immunolog, Kantonsspital St. Gallen, St.Gallen, Sankt Gallen, Switzerland, ⁴Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Vaud, Switzerland, ⁵Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland, ⁶Institute of Immunology, University of Heidelberg, Heidelberg, Germany, ⁷Division of Rheumatology and Clinical Immunology, Medical Centre - University of Freiburg, Freiburg, Germany
Background/Purpose: There is a lack of reliable biomarkers for disease activity in SLE. While C3a, an anaphylatoxin generated during of complement activation, could be predictive…
Abstract Number: 952 • 2019 ACR/ARP Annual Meeting
Rate of Thirty-Day Readmissions in Systemic Lupus Erythematosus Rivals Congestive Heart Failure and Exceeds the General Medicare Population
Ann Chodara¹, Xing Wang ¹, Fangfang Shi ¹, Shivani Garg ¹, Ryan Powell ¹, Maria Schletzbaum ¹, Ann Sheehy ¹, Amy Kind ¹ and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Medicare measures readmissions within 30 days of hospitalization across several conditions as a marker of care quality. While not currently a reporting condition, in…
Abstract Number: 1105 • 2019 ACR/ARP Annual Meeting
Relationships Among Cognitive Emotion Regulation, Body Image, Family and Marital Function and Quality of Life in Chinese Female Patients with Systemic Lupus Erythematosus
Huilin Zhang ¹, Lezhi Li ², Mengyue Chen ² and Qing Zhang³, ¹Clinical Nursing Teaching and Research Section, Second Xiangya Hospital, Central South University, Changsha, Hunan, China (People's Republic), ²Xiangya Nursing School, Central South University, Changsha, Hunan, China (People's Republic), ³Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China (People's Republic)
Background/Purpose: At present, there are few researches on cognitive emotional regulation, body image, family and marital function, and life quality of female patients with systemic…
Abstract Number: 1570 • 2019 ACR/ARP Annual Meeting
Can the Montreal Cognitive Assessment (MoCA) Improve the Automated Neuropsychological Assessment Metrics (ANAM) Performance in Screening for Cognitive Impairment in Lupus Patients?
Oshrat Tayer-Shifman¹, Robin Green ², Dorcas Beaton ³, Lesley Ruttan ², Joan Wither ⁴, Maria Tartaglia ⁵, Mahta Kakvan ¹, Sabrina Lombardi ², Nicole Anderson ¹, Jiandong Su ¹, Dennisse Bonilla ¹, Moe Zandy ¹, May Choi ⁶, Marvin Fritzler ⁶ and Zahi Touma ⁷, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³St. Michael's Hospital, Toronto, ON, Canada, ⁴University Health Network, Krembil Research Institute, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: : In a related study, we have shown evidence to support the validity of the Automated Neuropsychological Assessment Metrics (ANAM) for the screening of…
Abstract Number: 1615 • 2019 ACR/ARP Annual Meeting
The Effects of Anti-glutamate Receptor Subunit Antiantibodies on Systemic Lupus Erythematosus Without Neuropsychiatric Involvement
Yoshiyuki Arinuma ¹, Yasuhiro Hasegawa ¹, Takumi Muramatsu¹, Yu Matsueda ¹ and Kunihiro Yamaoka ¹, ¹Department of Rheumatology and Infectious Diseaes, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
Background/Purpose: Autoantibodies against N-methyl-D-aspartate receptor subunit GluN2 (anti-GluN2) in the cerebrospinal fluid are known to be related with the development of diffuse psychiatric/neuropsychological manifestations in…
Abstract Number: 1825 • 2019 ACR/ARP Annual Meeting
Comparison of the Thrombosis Risk Score with Triple Positivity in SLE Thrombosis
Michelle Petri¹, Jessica Li ¹, John Conklin ², Tyler O'Malley ³, Jo-Anne Ligayon ², Leilani Wolover ² and Thierry Dervieux ², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Exagen, Vista, CA, ³Exagen, Oceanside, CA
Background/Purpose: We previously developed a Thrombosis Risk Score, a sum of three factors: lupus anticoagulant (by RVVT confirm); low C3; and C4d bound to platelets.…
Abstract Number: 2033 • 2019 ACR/ARP Annual Meeting
IRAK4 Inhibition Suppresses TLR7, TLR9, and SLE Serum-Induced IFNA Production in Primary Human Plasmacytoid Dendritic Cells
Angie Hammond¹, Sean Parghi ¹, Nathan Wright ¹, Ethan Grant ¹, James Taylor ¹ and Matthew Warr ¹, ¹Gilead Sciences, Inc., Foster City, CA
Background/Purpose: A hallmark of lupus is the presence of antinuclear autoantibodies, including those against RNA-protein complexes and double-stranded DNA (dsDNA).1,2 FcγR-mediated internalization of these nucleic…
Abstract Number: 2518 • 2019 ACR/ARP Annual Meeting
Time to Lupus Low Disease Activity State: Role of African-American Ethnicity
Hakan Babaoglu¹, Jessica Li ², Daniel Goldman ³, Laurence Magder ⁴ and Michelle Petri ², ¹Gazi University School of Medicine, Ankara, Turkey, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Lupus Low Disease Activity State (LLDAS) is a potential treat to target goal in systemic lupus erythematosus (SLE). It is well established that SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].